MASATAKA SUZUKI to T-Lymphocytes
This is a "connection" page, showing publications MASATAKA SUZUKI has written about T-Lymphocytes.
Connection Strength
1.245
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
Score: 0.491
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.380
-
Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
Score: 0.118
-
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther. 2021 02 03; 29(2):505-520.
Score: 0.092
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.074
-
Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In?Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors. Immunohorizons. 2024 08 01; 8(8):598-605.
Score: 0.030
-
Integration of ?-deficient CARs into the CD3? gene conveys potent cytotoxicity in T and NK cells. Blood. 2024 06 20; 143(25):2599-2611.
Score: 0.030
-
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 12 15; 83(24):4047-4062.
Score: 0.029